Percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy

• Published in: BMC cardiovascular disorders Vol. 25; no. 1; pp. 564 - 10
• Main Authors: Tian, Aiju, Cheng, Yunjiu, Jia, Yuhe, Zhang, Tianjing, Li, Jiaju, Chen, Xuhua, Liu, Jun, Guo, Xiaogang, Sun, Qi, Tang, Min, Chen, Keping, Yao, Yan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.08.2025; BioMed Central; BMC
• Subjects: Ablation; Ablation (Surgery); Adult; Aged; Arrhythmia; Beta blockers; Cardiac arrhythmia; Cardiac patients; Cardiomyopathy; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Hypertrophic - diagnostic imaging; Cardiomyopathy, Hypertrophic - physiopathology; Cardiomyopathy, Hypertrophic - surgery; Cardiovascular magnetic resonance imaging; Care and treatment; Catheter Ablation - adverse effects; Catheter Ablation - methods; Catheters; Echocardiography; Edema; Electrophysiologic Techniques, Cardiac; Fainting; Female; Heart; Heart diseases; Heart function; Humans; Hypertrophic obstructive cardiomyopathy; Magnetic resonance imaging; Male; Methods; Middle Aged; Pacemakers; Patient outcomes; Patients; Radiofrequency ablation; Recovery of Function; Septal radiofrequency ablation; Software; Statistical analysis; Tamponade; Time Factors; Treatment Outcome; Veins & arteries; Ventricle; Ventricular Function, Left; Young Adult; China; United States > US; Cardiovascular magnetic resonance imaging; Heart function; Septal radiofrequency ablation; Hypertrophic obstructive cardiomyopathy

Percutaneous endocardial septal radiofrequency ablation (PESA) shows promise as a treatment for hypertrophic obstructive cardiomyopathy (HOCM). We aimed to explore the efficacy and safety of PESA require further study during a long-term follow-up. We enrolled 25 patients HOCM who underwent PESA. The...